AU2018287145B2 - Modified L-asparaginase - Google Patents

Modified L-asparaginase Download PDF

Info

Publication number
AU2018287145B2
AU2018287145B2 AU2018287145A AU2018287145A AU2018287145B2 AU 2018287145 B2 AU2018287145 B2 AU 2018287145B2 AU 2018287145 A AU2018287145 A AU 2018287145A AU 2018287145 A AU2018287145 A AU 2018287145A AU 2018287145 B2 AU2018287145 B2 AU 2018287145B2
Authority
AU
Australia
Prior art keywords
ala
ala pro
pro ala
asparaginase
modified protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018287145A
Other languages
English (en)
Other versions
AU2018287145A1 (en
Inventor
Lars Friedrich
Anne O'donnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Ireland Ltd
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17177237.9A external-priority patent/EP3418383A1/en
Priority claimed from US15/671,086 external-priority patent/US10174302B1/en
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of AU2018287145A1 publication Critical patent/AU2018287145A1/en
Application granted granted Critical
Publication of AU2018287145B2 publication Critical patent/AU2018287145B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82Asparaginase (3.5.1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001Asparaginase (3.5.1.1)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2018287145A 2017-06-21 2018-06-21 Modified L-asparaginase Active AU2018287145B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762523061P 2017-06-21 2017-06-21
EP17177237.9A EP3418383A1 (en) 2017-06-21 2017-06-21 Modified l-asparaginase
US62/523,061 2017-06-21
EP17177237.9 2017-06-21
US15/671,086 US10174302B1 (en) 2017-06-21 2017-08-07 Modified L-asparaginase
US15/671,086 2017-08-07
PCT/EP2018/066647 WO2018234492A1 (en) 2017-06-21 2018-06-21 L-ASPARAGINASE MODIFIED

Publications (2)

Publication Number Publication Date
AU2018287145A1 AU2018287145A1 (en) 2020-02-06
AU2018287145B2 true AU2018287145B2 (en) 2024-04-18

Family

ID=64737515

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018287145A Active AU2018287145B2 (en) 2017-06-21 2018-06-21 Modified L-asparaginase

Country Status (15)

Country Link
EP (2) EP4180525A1 (enExample)
JP (2) JP7808424B2 (enExample)
KR (1) KR102727396B1 (enExample)
CN (1) CN111315878B (enExample)
AU (1) AU2018287145B2 (enExample)
BR (1) BR112019027479A2 (enExample)
CA (1) CA3068100A1 (enExample)
DK (1) DK3642340T3 (enExample)
ES (1) ES2979314T3 (enExample)
FI (1) FI3642340T3 (enExample)
IL (1) IL271504B2 (enExample)
MX (2) MX2019015502A (enExample)
SA (2) SA519410870B1 (enExample)
SG (1) SG11201912625QA (enExample)
WO (1) WO2018234492A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017109087A1 (en) 2015-12-22 2017-06-29 Xl-Protein Gmbh Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
SG11201912625QA (en) * 2017-06-21 2020-01-30 Jazz Pharmaceuticals Ireland Ltd Modified l-asparaginase
US20200354706A1 (en) * 2017-11-22 2020-11-12 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
CA3156066A1 (en) * 2019-10-25 2021-04-29 Mi Rim Choi Recombinant l-asparaginase
AU2021410080A1 (en) * 2020-12-23 2023-06-22 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins
WO2022211829A1 (en) 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20260007728A1 (en) 2022-07-14 2026-01-08 Jazz Pharmaceuticals Ireland Ltd. Combination therapies involving l-asparaginase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221882B2 (en) * 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8519753D0 (en) * 1985-08-06 1985-09-11 Health Lab Service Board Production of 1-asparaginase
GB9017002D0 (en) * 1990-08-02 1990-09-19 Health Lab Service Board Improved method for the purification of erwina l-asparaginase
US7985548B2 (en) 2006-03-03 2011-07-26 The United States Of America As Represented By The Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
EP2851424B1 (en) * 2007-03-09 2016-09-21 Novozymes A/S Thermostable asparaginases
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
WO2011003633A1 (en) * 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
JP6355563B2 (ja) 2012-02-27 2018-07-11 アムニクス オペレーティング インコーポレイテッド Xten共役組成物およびそれを製造する方法
SG11201912625QA (en) * 2017-06-21 2020-01-30 Jazz Pharmaceuticals Ireland Ltd Modified l-asparaginase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221882B2 (en) * 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TANG S-S ET AL: PROTEIN EXPRESSION AND PURIFICAT, ACADEMIC PRESS, SAN DIEGO, CA, vol. 34, no. 2, 1 April 2004 (2004-04-01), pages 296 - 301, XP004493237, ISSN: 1046-5928, DOI: 10.1016/J.PEP.2003.11.012 *

Also Published As

Publication number Publication date
FI3642340T3 (fi) 2024-06-18
JP7770352B2 (ja) 2025-11-14
KR102727396B1 (ko) 2024-11-08
IL271504A (en) 2020-02-27
EP4180525A1 (en) 2023-05-17
MX2019015502A (es) 2020-07-28
CN111315878B (zh) 2024-04-26
KR20200030065A (ko) 2020-03-19
IL271504B1 (en) 2024-01-01
SA519410870B1 (ar) 2023-03-06
CA3068100A1 (en) 2018-12-27
SA522433360B1 (ar) 2024-06-23
DK3642340T3 (da) 2024-06-03
JP7808424B2 (ja) 2026-01-29
AU2018287145A1 (en) 2020-02-06
IL271504B2 (en) 2024-05-01
ES2979314T3 (es) 2024-09-25
EP3642340B1 (en) 2024-03-20
RU2020101972A3 (enExample) 2021-11-09
EP3642340A1 (en) 2020-04-29
MX2024015050A (es) 2025-01-09
CN111315878A (zh) 2020-06-19
RU2020101972A (ru) 2021-07-21
JP2023081915A (ja) 2023-06-13
JP2020528743A (ja) 2020-10-01
WO2018234492A1 (en) 2018-12-27
BR112019027479A2 (pt) 2020-09-15
SG11201912625QA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
AU2018287145B2 (en) Modified L-asparaginase
US20240076643A1 (en) Modified l-asparaginase
EP3418383A1 (en) Modified l-asparaginase
US12441992B2 (en) Method of treating AML with PEGylated l-asparaginase
EP2451486B1 (en) Pegylated l-asparaginase
EP4015526A1 (en) Recombinant interleukin-15 analog
RU2775696C2 (ru) Модифицированная l-аспарагиназа
HK40090811A (en) Modified l-asparaginase
HK40029594B (en) Modified l-asparaginase
HK40029594A (en) Modified l-asparaginase
CN114854729A (zh) 定向化学偶联门冬酰胺酶突变体及其制备方法和应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)